Novo Nordisk A/S (NVO)
Pre-market:
| Previous close | 132.80 |
| Open | 135.04 |
| Bid | 133.55 x 900 |
| Ask | 133.61 x 900 |
| Day's range | 133.76 - 135.86 |
| 52-week range | 75.56 - 138.28 |
| Volume | |
| Avg. volume | 4,355,373 |
| Market cap | 602.599B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 46.97 |
| EPS (TTM) | 2.88 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | 1.37 (1.01%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 147.72 |
Fool.co.ukSell in May? I bought these 3 magnificent growth stocks last month!
Edward Sheldon believes these three growth stocks could generate fantastic returns for his investment portfolio in the years ahead. The post Sell in May? I bought these 3 magnificent growth stocks last month! appeared first on The Motley Fool UK.
Investor's Business DailyS&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Intuitive Surgical and Universal Health are all trading in or near buy zones. Medical stocks are often viewed as defensive growth stocks, because their growth is insulated from economic swings due to the government or insurance covering most of the costs. Eli Lilly is in a buy zone while weight-loss drug rival and fellow IBD Leaderboard member Novo Nordisk is setting up.
The TelegraphThe ‘hardcore’ scientists shifting the dial on obesity
When Nadeem Sarwar got a call asking him to work on stopping people becoming obese, he was “quite confused”.
